%PDF-1.4
%
76 0 obj
<>
endobj
73 0 obj
<>
endobj
139 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-03T13:24:56Z
2024-03-29T02:49:43-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T02:49:43-07:00
application/pdf
Heather
2001-521.mar
uuid:d50607b7-1dd1-11b2-0a00-520827fd5800
uuid:d50607b9-1dd1-11b2-0a00-6a0000000000
endstream
endobj
62 0 obj
<>
endobj
63 0 obj
<>
endobj
77 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
20 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
28 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
36 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
44 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
47 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
173 0 obj
[177 0 R]
endobj
174 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 71.6 714.5293 Tm
[(Prog Brain Res 1996;1)36.9 (13:161-84.)]TJ
-0.00011 Tc -1.25 -1.25 Td
[(4.)-500.1 (Spengler RN, Chensue SW)91.7 (, Giacherio DA, Blenk N, Kunkel SL.)]TJ
0 Tc 1.25 -1.25 Td
[(Endogenous norepinephrine regulates tumor necrosis factor)19.8 (-alpha)]TJ
0 -1.25 TD
(production from macrophages in vitro. J Immunol 1994;)Tj
0 Tw T*
(152:3024-31.)Tj
-0.00011 Tc 0.02499 Tw -1.25 -1.25 Td
[(5.)-500.1 (Malfait )54.8 (AM, Malik )54.8 (AS, Marinova-Mutafchieva L, Butler DM, Maini)]TJ
0 Tc 1.25 -1.25 Td
[(RN, Feldmann M. )17.8 (The beta2-adrener)17.8 (gic agonist salbutamol is a)]TJ
T*
(potent suppressor of established collagen-induced arthritis:)Tj
T*
(mechanisms of action. J Immunol 1999;162:6278-83.)Tj
-0.00011 Tc -1.25 -1.25 Td
[(6.)-500.1 (Sanders )17.7 (VM, Baker RA, Ramer)19.7 (-Quinn DS, Kasprowicz DJ, Fuchs)]TJ
1.25 -1.25 Td
[(BA, Street NE. Dif)17.7 (ferential expression of the beta2-adrener)17.7 (gic)]TJ
0 Tc T*
[(receptor by )17.8 (Th1 and )17.8 (Th2 clones: implications for cytokine)]TJ
T*
(production and B cell help. J Immunol 1997;158:4200-10.)Tj
-1.25 -1.25 Td
[(7.)-500 (Kof)17.8 (f )17.8 (WC, Fann )54.9 (A)129.2 (V)129.1 (, Dunegan MA, Lachman LB. Catecholamine-)]TJ
1.25 -1.25 Td
[(induced suppression of interleukin-1 production. L)54.9 (ymphokine Res)]TJ
0 Tw T*
(1986;5:239-47.)Tj
0.0249 Tw -1.25 -1.25 Td
[(8.)-500 (Elenkov IJ, Papanicolaou DA, )17.7 (W)39.8 (ilder RL, Chrousos GP)110.8 (. Modulatory)]TJ
1.25 -1.25 Td
[(ef)17.8 (fects of glucocorticoids and catecholamines on human )]TJ
T*
(interleukin-12 and interleukin-10 production: clinical implications.)Tj
-0.02991 Tw T*
[(Proc Assoc Am )-54.9 (Physicians )-54.9 (1996;108:374-81.)]TJ
0.0249 Tw -1.25 -1.25 Td
[(9.)-500 (Whalen MM, Bankhurst )54.8 (AD. Ef)17.8 (fects of beta-adrener)17.8 (gic receptor )]TJ
1.25 -1.25 Td
(activation, cholera toxin and forskolin on human natural killer cell)Tj
T*
(function. Biochem J 1990;272:327-31.)Tj
-1.75 -1.25 Td
[(10.)-500 (Schedlowski M, Falk )54.8 (A, Rohne )54.8 (A, et al. Catecholamines induce)]TJ
1.75 -1.25 Td
(alterations of distribution and activity of human natural killer \(NK\))Tj
T*
(cells. J Clin Immunol 1993;13:344-51.)Tj
-1.7131 -1.25 Td
[(1)36.9 (1.)-500 (Boomershine CS, Lafuse )17.7 (WP)110.8 (, Zwilling BS. Beta2-adrener)17.8 (gic)]TJ
1.7131 -1.25 Td
(receptor stimulation inhibits nitric oxide generation by)Tj
T*
(Mycobacterium avium infected macrophages. J Neuroimmunol)Tj
0 Tw T*
(1999;101:68-75.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(12.)-500.1 (Miller LE, J\374sten HP)110.7 (, Sch\366lmerich J, Straub RH. )17.7 (The loss of)]TJ
0 Tc 1.75 -1.25 Td
(sympathetic nerve fibers in the synovial tissue of patients with)Tj
T*
(rheumatoid arthritis is accompanied by increased norepinephrine)Tj
-0.00011 Tc T*
[(release from synovial macrophages. F)73.9 (ASEB J 2000;14:2097-107.)]TJ
0 Tc -1.75 -1.25 Td
[(13.)-500 (Raap )17.7 (T)74 (,)0.1 ( J\374sten HP)110.8 (, Miller LE, Cutolo M, Sch\366lmerich J, Straub RH.)]TJ
-0.00011 Tc 1.75 -1.25 Td
(Neurotransmitter modulation of interleukin 6 \(IL-6\) and IL-8)Tj
0 Tc T*
(secretion of synovial fibroblasts in patients with rheumatoid arthritis)Tj
T*
(compared to osteoarthritis. J Rheumatol 2000;27:2558-65.)Tj
-1.75 -1.25 Td
[(14.)-500 (Muller)19.8 (-Ladner U, Roberts CR, Franklin BN, et al. Human IL-1Ra)]TJ
1.75 -1.25 Td
(gene transfer into human synovial fibroblasts is chondroprotective. )Tj
T*
(J Immunol 1997;158:3492-8.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(15.)-500.1 (Straub RH, Lang B, Falk )17.7 (W)91.7 (, Sch\366lmerich J, Singer EA. In vitro)]TJ
0 Tc 1.75 -1.25 Td
(superfusion method for the investigation of nerve-immune cell)Tj
T*
(interaction in murine spleen. J Neuroimmunol 1995;61:53-60.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(16.)-500.1 (Straub RH, Herrmann M, Berkmiller G, et al. Neuronal regulation of)]TJ
0 Tc 1.75 -1.25 Td
[(interleukin 6 secretion in murine spleen: )54.9 (Adrener)17.8 (gic and opioider)17.8 (gic)]TJ
T*
(control. J Neurochem 1997;68:1633-9.)Tj
-1.75 -1.25 Td
[(17.)-500 (Straub RH, Schaller )17.7 (T)74 (, Miller LE, et al. Neuropeptide )36.8 (Y)]TJ
1.75 -1.25 Td
(cotransmission with norepinephrine in the sympathetic nerve-)Tj
T*
[(macrophage interplay)64.9 (. J Neurochem 2000;75:2464-71.)]TJ
-1.75 -1.25 Td
[(18.)-500 (Bevan JA, Su C. )17.8 (V)111.1 (ariation of intra- and perisynaptic adrener)17.8 (gic)]TJ
1.75 -1.25 Td
(transmitter concentrations with width of synaptic cleft in vascular)Tj
-0.00011 Tc T*
[(tissue. J Pharmacol Exp )17.7 (Ther 1974;190:30-8.)]TJ
0 Tc -1.75 -2.5 Td
[(19.)-500 (Bevan JA. Some functional consequences of variation in adrener)17.8 (gic)]TJ
1.75 -1.25 Td
(synaptic cleft width and in nerve density and distribution. Fed Proc)Tj
0 Tw T*
(1977;36:2439-43.)Tj
0.0249 Tw -1.75 -1.25 Td
[(20.)-500 (Hartung HP)110.8 (, )17.7 (T)69.8 (oyka KV)128.9 (. )54.8 (Activation of macrophages by substance P:)]TJ
1.75 -1.25 Td
(induction of oxidative burst and thromboxane release. Eur J)Tj
T*
(Pharmacol 1983;89:301-5.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(21.)-500.1 (W)79.7 (agner F)79.7 (, Fink R, Hart R, Dancygier H. Substance P)-238.2 (enhances)]TJ
0 Tc 34.75 75 Td
(interferon-gamma production by human peripheral blood)Tj
T*
(mononuclear cells. Regul Pept 1987;19:355-64.)Tj
-1.75 -1.25 Td
[(22.)-500 (Lotz M, )17.7 (V)111.1 (aughan JH, Carson DA. Ef)17.8 (fect of neuropeptides on)]TJ
1.75 -1.25 Td
(production of inflammatory cytokines by human monocytes. Science)Tj
0 Tw T*
(1988;241:1218-21.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(23.)-500.1 (Kavelaars )54.8 (A, Broeke D, Jeurissen F)79.7 (,)-0.1 ( et al. )54.8 (Activation of human)]TJ
0 Tc 1.75 -1.25 Td
[(monocytes via a non-neurokinin substance P)-238.1 (receptor that is coupled)]TJ
T*
[(to Gi protein, calcium, phospholipase D, MAP)-238.1 (kinase, and IL-6)]TJ
T*
(production. J Immunol 1994;153:3691-9.)Tj
-1.75 -1.25 Td
[(24.)-500 (Rameshwar P)110.8 (,)0.1 ( Gascon P)110.8 (, Ganea D. Stimulation of IL-2 production in)]TJ
1.75 -1.25 Td
[(murine lymphocytes by substance P)-238.1 (and related tachykinins. )]TJ
T*
(J Immunol 1993;151:2484-96.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(25.)-500.1 (Lieb K, Fiebich BL, Ber)17.7 (ger M, Bauer J, Schulze-Osthof)17.7 (f K. )17.7 (The)]TJ
1.75 -1.25 Td
[(neuropeptide substance P)-238.2 (activates transcription factor NF-kappa B)]TJ
0 Tc T*
(and kappa B-dependent gene expression in human astrocytoma cells.)Tj
T*
(J Immunol 1997;159:4952-8.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(26.)-500.1 (Renz H, Gong JH, Schmidt )54.8 (A, Nain M, Gemsa D. Release of tumor)]TJ
0 Tc 1.75 -1.25 Td
[(necrosis factor)19.8 (-alpha from macrophages. Enhancement and)]TJ
T*
(suppression are dose-dependently regulated by prostaglandin E2 and)Tj
T*
(cyclic nucleotides. J Immunol 1988;141:2388-93.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(27.)-500.1 (Severn )54.8 (A, Rapson NT)73.9 (, Hunter CA, Liew FY)128.8 (. Regulation of tumor)]TJ
0 Tc 1.75 -1.25 Td
[(necrosis factor production by adrenaline and beta- adrener)17.8 (gic)]TJ
T*
(agonists. J Immunol 1992;148:3441-5.)Tj
-1.75 -1.25 Td
[(28.)-500 (Le )17.8 (V)60.1 (raux )17.8 (V)129.1 (, Chen )36.9 (YL, Masson I, et al. Inhibition of human)]TJ
1.75 -1.25 Td
[(monocyte )17.7 (TNF production by adenosine receptor agonists. Life Sci)]TJ
0 Tw T*
(1993;52:1917-24.)Tj
0.0249 Tw -1.75 -1.25 Td
[(29.)-500 (Hasko G, Szabo C, Nemeth ZH, Kvetan )17.7 (V)129.1 (,)0.1 ( Pastores SM, )17.7 (V)60.1 (izi ES.)]TJ
-0.00011 Tc 1.75 -1.25 Td
[(Adenosine receptor agonists dif)17.7 (ferentially regulate IL-10, )17.7 (TNF-)]TJ
0 Tc T*
[(alpha, and nitric oxide production in RA)79.8 (W)-257.2 (264.7 macrophages and)]TJ
T*
(in endotoxemic mice. J Immunol 1996;157:4634-40.)Tj
-1.75 -1.25 Td
[(30.)-500 (Bouma MG, Stad RK, van den )17.7 (W)39.8 (ildenber)17.8 (g F)74 (A, Buurman )17.7 (W)110.8 (A)0.2 (.)]TJ
1.75 -1.25 Td
[(Dif)17.8 (ferential regulatory ef)17.8 (fects of adenosine on cytokine release by)]TJ
T*
(activated human monocytes. J Immunol 1994;153:4159-68.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(31.)-500.1 (Koshiba M, Kojima H, Huang S, )54.8 (Apasov S, Sitkovsky MV)128.8 (. Memory)]TJ
0 Tc 1.75 -1.25 Td
[(of extracellular adenosine )54.9 (A2A)-220.1 (puriner)17.8 (gic receptor)19.8 (-mediated)]TJ
T*
[(signaling in murine )17.8 (T)-257.2 (cells. J Biol Chem 1997;272:25881-9.)]TJ
-1.75 -1.25 Td
[(32.)-500 (Blalock JE, Smith EM. Human leukocyte interferon: structural and)]TJ
1.75 -1.25 Td
(biological relatedness to adrenocorticotropic hormone and)Tj
-0.00011 Tc T*
[(endorphins. Proc Natl )54.8 (Acad Sci USA)-220.2 (1980;77:5972-4.)]TJ
0 Tc -1.75 -1.25 Td
[(33.)-500 (Reynolds H, Nathan P)110.8 (,)0.1 ( Srivastava LS, Hess EV)128.9 (. Release of estradiol)]TJ
1.75 -1.25 Td
[(from fetal bovine serum by rat thymus, spleen, kidney)64.9 (, lung and)]TJ
T*
[(lung macrophage cultures. Endocrinology 1982;1)36.8 (10:2213-5.)]TJ
-1.75 -1.25 Td
[(34.)-500 (Kawaguchi-Nagata K, )17.7 (W)79.8 (atanabe )17.7 (T)74 (, )36.8 (Y)100.1 (amatodani )54.8 (A, et al. In vitro)]TJ
1.75 -1.25 Td
(increase of histidine decarboxylase activity and release of histamine)Tj
T*
[(by peritoneal resident cells of mast cell-deficient )17.8 (W/Wv mice;)]TJ
T*
[(possible involvement of macrophages. J Biochem \(T)69.8 (okyo\))]TJ
0 Tw T*
(1988;103:24-30.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(35.)-500.1 (Lolait SJ, Clements JA, Markwick )54.8 (AJ, et al. Pro-opiomelanocortin)]TJ
0 Tc 1.75 -1.25 Td
(messenger ribonucleic acid and posttranslational processing of beta)Tj
T*
(endorphin in spleen macrophages. J Clin Invest 1986;77:1776-9.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(36.)-500.1 (Rinner I, Globerson )54.8 (A, Kawashima K, Korsatko )17.7 (W)91.7 (,)-0.1 ( Schauenstein K.)]TJ
0 Tc 1.75 -1.25 Td
[(A)-219.8 (possible role for acetylcholine in the dialogue between)]TJ
T*
(thymocytes and thymic stroma. Neuroimmunomodulation)Tj
0 Tw T*
(1999;6:51-5.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Miller)110.8 (, et al: Sympathoadr)36.9 (enal cells in RA)]TJ
0 Tw 61.4375 -0.0313 Td
(435)Tj
ET
0 0 0 0 scn
/GS0 gs
102.25 59.35 407.5 -10.83 re
f*
0.5 w
102.25 59.35 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
120 0 obj
<>
endobj
144 0 obj
<>
endobj
90 0 obj
<>
endobj
81 0 obj
<>
endobj
80 0 obj
<>
endobj
110 0 obj
<>stream
HVpTι&B $pL7&(n"] 0,U`@&t`@Aqyt@ Qq~w@t{s?] PdMtBqEW͌@@J?cI,u_в9?O@1缸sR|奁헏TNA!D~yݻz:F88
UX\#$/*JUʺI
Jʅ_|Q,ҪrtV*Xg+čP؆Džz}X&Fr0$<MXI[H@c;qv)b(/A5ק"ey,A#4}g`2
p@6X'oXUu7FS-~#j
zID0ᴜĝE.wE̳rUg0>l$8#f*ʱX۵T³qGLVOkldK30uĈK,01JmqP^ŭTv1Z6^&cyO,Z
xD)E&'e/oUE]^HVL$V Xd+s-{BN!zLzd-+HezByCu-Uh->a縗1K{5rUx>ON;ƽ$rkN-۸d%bbE[p3k#Y|1ITeV,:r-><3RJ~*OS+yE^?*JbyjCfi5Z1sQiE[iVl5߅30-'mfe,f670:}̳tѝ`2#wq!2]yD?FLjL1Kr@"jj::"vF_\7-WQe+'<FoȷF&"M[a6!(ټ8eP(uVe]r\iQ) 5K֨o3liLmVh֠jwpNv\lfgb><*kr9N_"$#